At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Rafael Fonseca (Mayo Clinic, Scottsdale, AZ) discusses multiple myeloma and amyloidosis.
In multiple myeloma, minimum residual disease (MRD) testing is receiving great interest in the evaluation of treatment and as a prognostic marker. In amyloidosis, proteasome inhibition is emerging as an important novel therapy.
Advertisement